Universal Technical Institute (NYSE: UTI) shareholders absorbed a sharp selloff after the Company lowered its fiscal 2026 baseline adjusted EBITDA outlook to above $135 million, down from more than $155 million — a reduction of roughly $20 million from the figure management had reaffirmed months earlier. Investors who lost money on UTI are encouraged to submit their loss information now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
The timeline: On the May 6, 2026 earnings call, Chief Financial Officer Bruce Schuman told investors, “we are pleased to reaffirm our fiscal 2026 outlook.” On the same call, Chief Executive Officer Jerome Grant stated, “we feel real confident that the starts aren’t going to fall anywhere near below and could be in the top part of the range.”
With the fiscal Q3 FY2026 results, the outlook was reset. Management attributed approximately 70% of the EBITDA reduction to weaker-than-expected fourth-quarter starts in the high-school auto and diesel channel, with the remainder tied to a faster mix shift toward shorter-duration, lower-margin programs. Quarterly revenue rose 7.2% year over year to $218.9 million.
Levi & Korsinsky is investigating potential securities law violations concerning statements made to UTI investors prior to the outlook reduction.
Shareholders who purchased UTI stock and suffered a loss are encouraged to have their losses evaluated at no cost.
WHY LEVI & KORSINSKY — Ranked in ISS Securities Class Action Services’ Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.
Frequently Asked Questions About the UTI Investigation
Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Universal Technical Institute made materially false or misleading statements regarding its fiscal 2026 profitability outlook and expected student starts. After the Company lowered baseline adjusted EBITDA guidance to above $135 million from more than $155 million, the stock declined sharply.
Q: Who is eligible to participate in the UTI investigation? A: Investors who purchased UTI stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.
Q: Who is conducting the UTI investigation? A: Levi & Korsinsky, LLP is investigating potential securities fraud claims on behalf of investors who purchased UTI securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors.
Q: What do UTI investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or (212) 363-7500.
Q: What is a lead plaintiff and why does it matter? A: If the investigation proceeds to legal action, a lead plaintiff is the investor the court appoints to represent the group of affected investors. Lead plaintiffs are typically investors with the largest documented losses. Contacting the firm during the investigation phase preserves that option.
Q: What if I already sold my UTI shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought UTI and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost to participate. Securities investigations and any resulting actions are generally handled on a contingency basis — no retainer and no out-of-pocket costs.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions.
Attorney Advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260812387747/en/
Media gallery
